VSIG2, Human (Biotinylated, HEK293, His)

VSIG2 is also known as CTXL (cortical thymocyte like-protein) . VSIG2 promotes malignant progression of pancreatic ductal adenocarcinoma through LAMtor2-mediated mTOR activation. VSIG2 can be used as a potential biomarker or therapeutic target for tumors. VSIG2 Protein, Human (Biotinylated, HEK293, His) is the recombinant human-derived VSIG2 protein, expressed by HEK293 , with C-His labeled tag.

Product Specifications

Product Name Alternative

VSIG2 Protein, Human (Biotinylated, HEK293, His), Human, HEK293

UNSPSC

12352202

Type

Recombinant Proteins

Assay Protocol

https://www.medchemexpress.com/cytokines/vsig2-protein-human-biotinylated-hek293-his.html

Molecular Formula

23584 (Gene_ID) Q96IQ7-1 (V24-A243) (Accession)

Molecular Weight

Approximately 24.6 kDa

References & Citations

[1]Cui Z, et al. Key Candidate Genes - VSIG2 of Colon Cancer Identified by Weighted Gene Co-Expression Network Analysis. Cancer Manag Res. 2021 Jul 15;13:5739-5750.|[2]Xu J, et al. VSIG2 promotes malignant progression of pancreatic ductal adenocarcinoma by enhancing LAMTOR2-mediated mTOR activation. Cell Commun Signal. 2023 Aug 25;21 (1) :223.|[3]Zhou X, et al. V-Set and immunoglobulin domain containing (VSIG) proteins as emerging immune checkpoint targets for cancer immunotherapy. Front Immunol. 2022 Sep 15;13:938470.